MedCity News September 27, 2024
Frank Vinluan

Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics.

Schizophrenia is currently treated with older medications with limited efficacy and troublesome side effects that lead many patients to stop taking them. The FDA has approved a novel Bristol Myers Squibb drug that takes a different approach to schizophrenia, introducing the first novel medication for the disorder in decades.

For patients, approval of the drug, Cobenfy, offers a new treatment option with better tolerability. For BMS, the late Thursday regulatory decision marks a payoff for its multi-billion dollar acquisition of the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Nearly half of FDA-authorized AI tools may provide little benefit
5 FDA decisions to watch in the fourth quarter - 2
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
FDA Roundup: Agency Highlights from September 2024
COVID Preventive Drug Should Work Against Circulating Variants, FDA Now Says

Share This Article